Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Immunolux International Corp. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 2 distinct examiners and an equal number of distinct art units. This distribution suggests a diverse set of technical focuses within the pharmaceutical sector, as each active case is being reviewed by a different examiner in a separate administrative department at the USPTO.
Estella M Gustilo is identified as the busiest examiner for the company, currently handling 1 pending office action. Because the 2 total pending office actions are split between different examiners, the workload is evenly dispersed across the portfolio's assigned personnel. For the practitioner, this requires managing independent prosecution tracks. Success depends on navigating the specific preferences and examination styles of multiple art units simultaneously, as no single examiner holds a majority of the active cases. Each matter must be addressed according to its own unique technical and administrative context.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GUSTILO, ESTELLA M | 1 | 53.6% | +34.5% |
| NOBLE, MARCIA STEPHENS | 1 | 67.1% | +39.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18293257 | METHODS AND COMPOSITIONS FOR USING ACTIVATED LYMPHOCYTES IN THE TREATMENT OF DISEASE | GUSTILO, ESTELLA M | — |
| 17615018 | USE OF POXVIRUS WITH AUTOLOGOUS INDUCED PLURIPOTENT STEM CELLS FOR VACCINATION AND DISEASE THERAPY | NOBLE, MARCIA STEPHENS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18293257 | METHODS AND COMPOSITIONS FOR USING ACTIVATED LYMPHOCYTES IN THE TREATMENT OF DISEASE | GUSTILO, ESTELLA M | — |
| 17615018 | USE OF POXVIRUS WITH AUTOLOGOUS INDUCED PLURIPOTENT STEM CELLS FOR VACCINATION AND DISEASE THERAPY | NOBLE, MARCIA STEPHENS | — |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18293257 | METHODS AND COMPOSITIONS FOR USING ACTIVATED LYMPHOCYTES IN THE TREATMENT OF DISEASE | GUSTILO, ESTELLA M | 1646 | §101§102Other | Non-Final OA | — | Pending | Jan 29, 2024 |
| 17615018 | USE OF POXVIRUS WITH AUTOLOGOUS INDUCED PLURIPOTENT STEM CELLS FOR VACCINATION AND DISEASE THERAPY | NOBLE, MARCIA STEPHENS | 1632 | §102§103Other | Non-Final OA | — | Pending | Nov 29, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialImmunolux International Corp. has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
Estella M Gustilo has the most, with 1 of Immunolux International Corp.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.